Arrowhead Pharmaceuticals Inc ARWR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
-
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
-
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
-
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
-
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
-
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
-
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
-
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Trading Information
- Previous Close Price
- $65.45
- Day Range
- $64.50–65.76
- 52-Week Range
- $34.47–95.49
- Bid/Ask
- $63.50 / $66.00
- Shares Outstanding
- 141.25M
- Market Cap
- $9.15B
- Volume/Avg
- 4,501 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 40.47
- Price/Sales
- 13.58
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 711
- Website
- https://www.arrowheadpharma.com
Valuation
|
Metric
|
ARWR
|
|---|---|
Price/Earnings (Normalized) | 40.47 |
Price/Book Value | 19.63 |
Price/Sales | 13.58 |
Price/Cash Flow | — |
Price/Earnings
ARWR
Financial Strength
|
Metric
|
ARWR
|
|---|---|
Quick Ratio | 5.68 |
Current Ratio | 5.90 |
Interest Coverage | −2.29 |
Quick Ratio
ARWR
Profitability
|
Metric
|
ARWR
|
|---|---|
Return on Assets (Normalized) | −13.25% |
Return on Equity (Normalized) | −43.98% |
Return on Invested Capital (Normalized) | −17.70% |
Return on Assets
ARWR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<%$^$%H | LOCK|<>DX | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|q%WX^% | LOCK|FxHgk | $76B | |||
| Moderna Inc
MRNA
| LOCK|y?Jl>qj | LOCK|SX | $75B | |||
| argenx SE ADR
ARGX
| LOCK|%cD&$PB | LOCK|kZy | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H^shW&K | LOCK|$%! | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Qsg#^^z | LOCK|T?d$r | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Sw>>wW! | LOCK|!g<p> | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|Tfm@S# | LOCK|R@ | $24B | |||
| Incyte Corp
INCY
| LOCK|yx>^Ht# | LOCK|$hD | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^V%Gz$Y | LOCK|$P^ | $15B |
United States